Arix Bioscience
Arix Bioscience, a prominent player in the research and development services sector, is headquartered in Great Britain. Founded in 2016, the company has quickly established itself as a leader in the life sciences industry, focusing on the development of innovative therapies and technologies. Arix Bioscience operates primarily in the UK and Europe, leveraging its expertise to support early-stage biotechnology companies.
The firm is renowned for its unique approach to investment and development, providing not only capital but also strategic guidance to its portfolio companies. Arix's commitment to advancing healthcare solutions has positioned it as a key contributor to the biotech landscape, with notable achievements in fostering groundbreaking research. Through its dedication to innovation, Arix Bioscience continues to shape the future of medical science.
+1 vs industry average
Arix Bioscience’s score of 31 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Arix Bioscience?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Research Services has typical carbon intensity
Industry performance
The Research Services industry has reduced its overall emissions by 19% since 2018
Emissions trajectory 2020 – 2025
Reported emissions
Scope 3 accounts for ••• of total emissions.
Arix Bioscience's reported carbon emissions
Arix Bioscience, a Research and development services (73) company based in GB, reported a total of approximately 13.3 tonnes of CO2e emissions in 2022. This total is comprised of approximately 3.7 tonnes of CO2e from Scope 1 emissions and approximately 8.9 tonnes of CO2e from Scope 2 emissions (market-based). Scope 3 emissions for 2022 amounted to approximately 5.2 tonnes of CO2e.
In 2021, Arix Bioscience's total emissions were approximately 10.4 tonnes of CO2e, with approximately 4.9 tonnes of CO2e from Scope 1, approximately 7.8 tonnes of CO2e from Scope 2 (market-based), and approximately 2.9 tonnes of CO2e from Scope 3.
For 2020, the company reported approximately 5.0 tonnes of CO2e for Scope 1 emissions and approximately 5.1 tonnes of CO2e for Scope 2 emissions (market-based). Scope 3 emissions data was not disclosed for 2020.
Arix Bioscience has a long-term climate commitment to operate as a fully Net-Zero business by 2050 or sooner, aiming to remove more than 90% of its emissions by that point.
While no specific reduction targets are detailed for Arix Bioscience in the provided information, the company's reporting covers Scope 1, 2, and 3 emissions, indicating a commitment to understanding and managing its climate impact across its value chain. There is no indication of data being cascaded from a parent organisation.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Arix Bioscience’s Climate Goals (2030 & 2050)
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project